Clinical trials: Depression NOS
Depression
Clinical Study on the Safety and Efficacy of Dental Pulp Mesenchymal Cells in the Treatment of Depression
This is a single center phase I / II clinical trial. Randomized, blind and positive drug parallel control were used to evaluate the safety and effectiveness of dental pulp mesenchymal cell injection in the treatment of depression…
- Trial name
- NCT05127369
- Testing
- Dental pulp mesenchymal cell injection, Dental pulp mesenchymal cell vehicle, fluoxetine hydrochloride capsule
- Volunteers
- 48 people
- Sponsor
- CAR-T (Shanghai) Biotechnology Co., Ltd.
Depression
Implementing IntelliCare in Collaborative Care: A Quality Improvement Evaluation
The overarching aim of the proposed project is to conduct a pragmatic, quality improvement evaluation of the IntelliCare Platform for improving processes of care in the Rush Collaborative Care program, and improving patient…
- Trial name
- NCT04499729
- Testing
- IntelliCare, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 318 people
- Sponsor
- Adaptive Health, Inc
Major Depressive Disorder
A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder
A Study to Evaluate BMS-986511 in Adults with Major Depressive Disorder
- Trial name
- NCT07772531
- Testing
- BMS-986511
- Where
- 27 sites in United States, Czechia
- Volunteers
- 200 people
- Sponsor
- Bristol-Myers Squibb
Major Depressive Disorder
Duloxetine Versus Paroxetine for Major Depression
To determine if duloxetine works just as well as paroxetine in the treatment of major depressive disorder.
- Trial name
- NCT00489775
- Testing
- Duloxetine, Paroxetine
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Eli Lilly and Company
Depression
Study Comparing Outcomes for Patients With Treatment Resistant Depression Who Receive VNS Therapy at Different Doses
This is a postmarket medical device study. The objective of this study is to compare the safety and effectiveness of Vagus Nerve Stimulation (VNS) Therapy administered at different amounts of electrical charge for the treatment…
- Trial name
- NCT00305565
- Testing
- VNS Therapy
- Where
- 26 sites in United States
- Volunteers
- 331 people
- Sponsor
- Cyberonics, Inc.
Bipolar Depression
A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers
The purpose of this first in human (FIH) study is to investigate the safety, tolerability, pharmacokinetics ( how the body handles the drug) and pharmacodynamics (how the drug affects the body) of PF-04455242-01 in healthy adult…
- Trial name
- NCT00938301
- Testing
- PF-04455242
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Lymphoma Nonhodgkin
Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)
To ascertain the safety of Revlimid® Capsules 2.5 mg or 5 mg under the actual use conditions in patients who received R2 combination therapy with the drug and rituximab for the first time for relapsed or refractory follicular…
- Trial name
- NCT04618081
- Where
- Japan
- Volunteers
- 151 people
- Sponsor
- Celgene
Depressive Disorder
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Depression
The purpose of the study is to evaluate the efficacy and safety of SR58611A in elderly patients with depression.The primary objective is to evaluate the efficacy of a 700 mg dose of SR58611A compared to placebo in elderly…
- Trial name
- ZEPHIR (NCT00319709)
- Testing
- SR58611A
- Where
- 5 sites in Bulgaria, Finland and 3 more
- Volunteers
- 288 people
- Sponsor
- Sanofi
Treatment-Resistant Depression
NRX-101 Expanded Access
The purpose of this Expanded Access Treatment Protocol is to make NRX-101 available to patients who have treatment-resistant depression and who are unable to participate in, or do not have access to, the ongoing NRX-101 clinical…
- Trial name
- NRX-101 EAP (NCT05779267)
- Testing
- NRX-101
- Where
- United States
- Sponsor
- NeuroRx, Inc.
Bipolar Disorder
Study Evaluating Bifeprunox in Bipolar Depression
The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder.
- Trial name
- NCT00134459
- Testing
- Bifeprunox
- Where
- 40 sites in United States
- Volunteers
- 434 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depression
Bioequivalency Study of Sertraline Under Fed Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' Sertraline Tablets, 100 mg, to Zoloft® Tablets, 100 mg (Pfizer) under fed conditions using a single-dose, 2-treatment, 2-period, crossover design.
- Trial name
- NCT00601588
- Testing
- Sertraline
- Where
- Canada
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Depression, Anxiety
Meru Health Program to Treat Depression in Primary Care
Meru Health Inc. seeks to further validate the Meru Health Program (MHP) as a single solution to screening, referral, and treatment in primary care as compared to treatment as usual using a Randomized Controlled Trial (RCT) study…
- Trial name
- NCT05615662
- Testing
- Meru Health Program, Treatment as Usual
- Where
- United States
- Sponsor
- Meru Health, Inc.
Depressive Symptoms, Parkinson's Disease
Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn
The primary endpoint for this study is the clinical response after 12 weeks of treatment, defined as a change in total score from baseline depressive symptoms as measured by the Beck Depression Inventory-Amended (BDI-IA) total…
- Trial name
- ACCORDO (NCT01055379)
- Testing
- Rasagiline
- Where
- 12 sites in Italy
- Volunteers
- 121 people
- Sponsor
- Lundbeck Italia S.p.A.
Major Depressive Disorder
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)
- Trial name
- NCT06419608
- Testing
- BHV-7000
- Where
- 62 sites in United States
- Volunteers
- 336 people
- Sponsor
- Biohaven Therapeutics Ltd.
Pain, Depression
Study Evaluating Rhapsody Registry in Patients With Depression and Anxiety
The purpose of this study is to assess the prevalence of Major Depression and/or Anxiety Disorder in patients consulting the General Practitioner with acute or chronic painful physical symptoms and to identify risk factors.
- Conditions
- Pain, Depression, Anxiety Disorder
- Trial name
- NCT00241397
- Where
- 91 sites in Belgium
- Volunteers
- 2,560 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depression
RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive Episode
The study is a phase II, double-blind, randomized, placebo controlled, parallel, multicentric study in 110 patients with drug resistant depression.
- Trial name
- NCT03870776
- Testing
- MAP4343
- Where
- 10 sites in France
- Volunteers
- 126 people
- Sponsor
- Mapreg
Major Depressive Disorder
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder
To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo.
- Trial name
- NCT00072774
- Testing
- DVS-233 SR
- Volunteers
- 480 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depression, Suicide
Antidepressant Drug Exposure and Risk of Suicide Attempt Resulting in Medical Intervention in US Adults
The primary objective of the study is to estimate the incidence of suicide attempts resulting in a medical encounter or hospitalization in seven propensity matched cohorts of subjects: patients treated with duloxetine for…
- Trial name
- NCT00763724
- Volunteers
- 254,432 people
- Sponsor
- Eli Lilly and Company
Depression, Depressive Disorder
Digital Therapeutic for Adolescent Depressive Symptoms in Hematology, Oncology, and Weight Management
The primary aims of the proposed research are to assess the feasibility, acceptability, and preliminary evidence of efficacy of a self-guided, cognitive behavioral therapy (CBT)-based mobile app intervention (SparkRx) for the…
- Conditions
- Depression, Depressive Disorder, Depressive Symptoms, Depressive Episode
- Trial name
- NCT05351866
- Testing
- CBT-based mobile intervention for depression, Mobile control with education about depression
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Limbix Health, Inc.
Anxiety, Depression
Comparison of MMFS Dosages in Older Adults
This study is designed to compare the effectiveness of different doses of brain health supplement MMFS relative to placebo on cognition, mood, and sleep quality.
- Conditions
- Anxiety, Depression, Sleep Quality, Cognitive Impairment
- Trial name
- NCT03601169
- Testing
- Low Dose MMFS-205-SR, High Dose MMFS-205-SR
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Neurocentria, Inc.